Table 1 Summary of clinico–pathological data and results of thymomas
Clinicopathological data | HPyV7 | P16 | ProteinRb | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Lab ID | G. | Age | MG | Thym. type | Masaoka–Koga | Anti–AChR | IS/Ster. | IHC 2 t10 | Anti–Rb | phosRb | |
1–1 | F | 73 | + | B1/B2 | I | + | + | – | – | + | + |
1–2 | F | 75 | + | B1/B2 | I | + | + | – | – | + | + |
1–11 | F | 34 | + | B2 | I | + | – | – | ++ | + | + |
1–12 | F | 36 | + | A | I | – | + | – | – | – | – |
1–16 | F | 34 | + | A | I | + | + | – | – | + | + |
1–17 | M | 69 | + | AB | I | + | + | – | (+) | + | + |
1–18 | F | 47 | + | AB | I | + | + | – | (+) | (+) | (+) |
1–19 | M | 68 | – | AB | I | NA | NA | + | + | (+) | (+) |
1–21 | F | 38 | + | AB | I | + | – | – | – | + | – |
1–22 | M | 65 | + | AB/B2 | I | + | – | – | ++ | (+) | (+) |
1–28 | M | 38 | – | B1 | I | NA | NA | – | (+) | + | + |
1–31 | F | 82 | + | A | I | + | + | + | – | (+) | – |
1–32 | M | 47 | + | B2 | I | + | – | – | (+) | + | + |
1–34 | M | 59 | – | AB | I | NA | NA | + | + | + | + |
1–36 | F | 82 | – | AB | I | NA | NA | + | + | (+) | (+) |
1–39 | F | 78 | – | B1 | I | NA | NA | – | + | + | + |
1–43 | F | 78 | – | AB | I | NA | NA | (+) | – | + | + |
1–23 | M | 37 | + | AB | IIA | + | – | + | (+) | + | + |
1–24 | M | 68 | + | B2 | IIA | + | – | + | (+) | + | + |
1–33 | F | 43 | + | B2 | IIA | + | – | + | – | (+) | + |
1–35 | M | 45 | + | AB | IIA | + | – | + | – | + | (+) |
1–37 | M | 77 | + | AB | IIA | + | – | (+) | (+) | + | + |
1–38 | F | 80 | + | AB | IIA | + | + | – | – | – | + |
1–3 | F | 57 | + | B2/B3 | IIB | + | – | + | – | (+) | (+) |
1–5 | M | 37 | + | B3 | IIB | + | + | + | – | (+) | (+) |
1–7 | F | 79 | + | A | IIB | – | – | (+) | – | (+) | (+) |
1–8 | M | 58 | + | A/B2 | IIB | + | – | (+) | (+) | (+) | – |
1–9 | M | 64 | – | B2 | IIB | NA | NA | (+) | – | + | (+) |
1–15 | F | 53 | + | B3 | IIB | + | + | – | ++ | + | + |
1–26 | M | 65 | – | AB | IIB | NA | NA | – | + | + | – |
1–42 | F | 57 | + | AB | IIB | + | – | – | + | + | + |
1–10 | F | 73 | + | B3 | III | + | + | – | – | + | + |
1–13 | F | 54 | – | B2 | III | NA | NA | (+) | + | + | + |
1–20 | M | 64 | – | B3 | III | NA | NA | – | – | + | – |
1–41 | M | 65 | – | B3 | III | NA | NA | + | (+) | + | + |
1–4 | M | 40 | + | B2 | IVA | + | + | (+) | – | + | (+) |
1–30 | M | 37 | + | B2 | IVA | + | + | – | – | + | + |
17/37 | 19/37 | 35/37 | 31/37 | ||||||||
46 % | 51.4 % | 94.6 % | 83.8 % | ||||||||